One capture session.
Nine involuntary signal domains.
A family of indices.
Four live tests today: Balance, Eye Tracking, Cognitive, and rPPG heart rate concurrent. Two more, Simple Reaction Time and an Anti-Saccade prefrontal-inhibition probe, in integration this sprint. Additional biomarker domains on the roadmap.
Chronic Trace processes a short series of guided captures from a commodity camera-enabled device. Four live scored tests today: Balance, Eye Tracking, Cognitive, and rPPG heart rate captured concurrently with the eye-tracking video. Simple Reaction Time and an Anti-Saccade prefrontal- inhibition probe are wiring into the battery this sprint; additional biomarker domains are on the engineering roadmap. On devices whose front-facing sensor exposes an infrared stream, the platform additionally captures infrared-grade pupillometry. All live signal fuses through our Dispersion-Based Cognitive Intra-Individual Variability (d-CIIV) methodology into calibrated, indication-specific indices.
The capture session,
moment by moment.
Four scored tests run in sequence: Balance, Eye Tracking, Cognitive, and rPPG heart rate extracted concurrently from the eye-tracking video. Simple Reaction Time and an Anti-Saccade prefrontal-inhibition probe are in integration this sprint. Additional biomarker domains are on the engineering pipeline; the labels below mark current status honestly.
Coherence, not performance.
Healthy brain function exhibits tight coupling across pupillary, oculomotor, postural, and autonomic systems. Pathology — whether acute (concussion, stroke) or chronic (CTE, depression, prodromal psychosis, neurodegeneration) — manifests as dispersion: signals that drift apart from one another and from the individual's personal baseline.
The Dispersion-Based Cognitive Intra-Individual Variability framework converts that dispersion into a continuous, calibrated, longitudinally-comparable index. We measure how coherent the brain's systems remain over time, against the subject's own prior captures.
The platform deliberately pairs voluntary task performance (the cognitive screens, the held stances, the simple reaction-time response) with involuntary biomarker channels (pupillary constriction to a light flash, saccadic latency, postural micro-corrections, autonomic measurements). The divergence between the two is itself a flagged signal. A subject attempting to under-perform a baseline degrades the voluntary channels while the involuntary channels remain physiologically anchored. That divergence is detectable. It is the architectural answer to the baseline-sandbagging and post-injury-concealment patterns that defeat every self-report screening tool in use today.
One capture.
Many indications.
The launch indication is concussion, TBI, and CTE risk monitoring. The same capture session yields signal sufficient to extend across stroke triage, psychiatric severity grading, suicide-risk stratification, neurodegeneration and dementia risk, oncologic detection from ocular and retinal signs, infectious disease detection, and treatment-response monitoring.
Concussion Likelihood Index (CLI)
Continuous 0 – 100 dispersion score; the launch indication.
Individual Sensitivity Profile (ISP)
Per-subject calibration that lets the platform compare a person to themselves.
Predictive Safe Activity Threshold (PSAT)
Return-to-play and operational-readiness signal.
TBI Severity Classification
Acute and subacute traumatic brain injury grading.
CTE Risk Index (CTE-RI)
Longitudinal monitoring of progressive neurodegenerative trends in living individuals.
Stroke Likelihood / Severity / LVO probability
Pre-imaging triage. Time-of-onset estimation.
Severity Indices — Depression, Anxiety, PTSD, Mania, Psychosis, Attention
Calibrated against PHQ-9, GAD-7, PCL-5, CAPS-5, YMRS, PANSS, and related reference instruments.
Suicide Risk Index (SRI)
Designed to remain informative in patients motivated to conceal ideation.
Treatment Response Probability Index
Serial monitoring during SSRI / SNRI, ketamine, esketamine, psilocybin-assisted therapy, TMS, ECT, and digital therapeutics.
Nine filings.
One interlocking portfolio.
Not nine unrelated ideas. One method, protected in layers — the scoring foundation, the signals that feed it, and the indications it extends into. Each filing reinforces the others.
U.S. provisional patent applications filed. No claim is made that any application has been granted, nor that any claim herein is allowable. Patent prosecution is ongoing.
For partners and researchers.
The platform is under active validation. Pilot collaborations, cohort partnerships, and pharmaceutical-trial endpoints are open to discussion.